Hammel Neurorehabilitation Centre and University Research Clinic
Hammel, Aarhus, 8450, Denmark
NCT Number: NCT06153017
Reliable prediction of upper limb (UL) function can guide clinicians in choosing relevant treatment, helps to set realistic goals for rehabilitation and will contribute to personalized and effective rehabilitation. TMS has been identified as a strong predictor of future UL function after stroke. With this project, the investigators want to implement the standard use of TMS examination for a defined patient group in the clinical setting and systematically evaluate the implementation process. The impact and perceived value of TMS in the clinical setting will be evaluated and the predictive value of TMS for the specific patient population will be assessed.
This study is active but is not currently recruiting participants.
Notify Me18 year and older
All sexes
Observational
Hammel, Aarhus, 8450, Denmark
Design Design: A prospective longitudinal implementation study. Setting and population: The implementation will take place at Hammel Neurorehabilitation Centre and University Research Clinic. The target population are patients with stroke.
Management The study will be organized by the Research Unit at Hammel Neurocenter, Iris Brunner, associate professor, PhD, in collaboration with the Center Management represented by head physician Kåre Eg Severinsen, MD, PhD and the unit for professional development, represented by Camilla Biering Lundquist PhD.
Evaluation of the implementation The RE-AIM framework, and its extension, the Practical Implementation Sustainability Model (PRISM) framework will be applied to guide and evaluate the implementation process. The RE-AIM framework has been used in numerous studies and hosts a homepage with comprehensive online resources for planning, evaluating and reporting implementation studies.
Briefly, it consists of the following components to evaluate the success of an implementation:
Reach. Refers to percent of individuals who are reached by the intervention. In the context of the present study, Reach would describe the number of patients for whom the TMS examination would be relevant, and the percentage of patients who received TMS, and reasons for not being examined.
Effectiveness: Entails the measurement of primary and broader outcomes. In this study, Effectiveness would assess the prediction accuracy for the specific population at the hospital.
Adoption. The level of actual uptake of the new intervention. Specifically in this study the number of referrals of relevant patients from different wards. Moreover, the number of involved staff (therapists, MDs) with a positive attitude to the TMS examination.
Implementation. Description of the actual resources and cost allocated, intervention fidelity, and acceptance.
Maintenance. Measures the long-term attrition to an intervention on an individual and a setting level.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 3 months after stroke
Assesses arm motor function, range 0-57 (best)
Time frame: 3 months after stroke
Assesses impairment for shoulder abduction and finger extension (0-10 best)
Time frame: 3 months after stroke
Assesses upper limb motor impairment
University of Aarhus
Other
Acronym: iTMS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05047172
Arterial Occlusive Diseases, Arteriosclerosis
Birmingham, Alabama, United States
View Trial DetailsNCT07710937
Brain Diseases, Cardiovascular Diseases
Multan Khurd, Pakistan
View Trial DetailsNCT07666906
Brain Diseases, Cardiovascular Diseases
Faisalābad, Punjab Province, Pakistan
View Trial DetailsNCT07708597
Atrophy, Brain Diseases
Nanjing, Jiangsu, China
View Trial Details